research use only

Eliglustat Glucosylceramide Synthase inhibitor

Name: Eliglustat
Brand: Selleck Chemicals
SKU: S7852
Availability: InStock
Rating: 5 (6 reviews)

Cat.No.S7852

Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome.

Eliglustat Glucosylceramide Synthase inhibitor Chemical Structure

Quality Control

Batch: S785201 DMSO]240 mg/mL]false]Ethanol]80 mg/mL]false]Water]Insoluble]false Purity: 99.8%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.8

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Glucosylceramide Synthase Inhibitors	Ibiglustat succinate

Solubility

In vitro
Batch:

DMSO : 240 mg/mL (593.26 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 80 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	6.000mg/ml (14.83mM)	Taking the 1 mL working solution as an example, add 50 μL of 120 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	404.54	Formula	C₂₃H₃₆N₂O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	491833-29-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	GENZ-112638			SMILES	CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	glucosylceramide synthase (In intact MDCK cells) 20 nM
In vitro	Eliglustat tartrate is designed and developed to inhibit glucosylceramide synthase, the enzyme that catalyzes the formation of glucosylceramide from UDP-glucose and ceramide.The inhibition of glucosylceramide synthase by this compound is highly specific. It displays limited or no activity against a variety of glycosidases. Additionally, no inhibition of sucrase or maltase is observed at drug concentrations up to 10 μM.
In vivo	Preclinical studies in normal mice, rats and dogs with i.v. and oral administration of this compound demonstrates significant dose-related decreases in spleen, kidney and liver glucosylceramide content, consistent with prior observations with the palmitoyl homologue.In rodents, this compound is rapidly metabolized with a half-life of 15–45 minutes.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22563139/ [2] https://pubmed.ncbi.nlm.nih.gov/20574539/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-02)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07138547	RECRUITING	Lymphoma	Chinese PLA General Hospital	2025-12-26	PHASE1; PHASE2
NCT06558773	RECRUITING	Colorectal Cancer	Chinese PLA General Hospital	2026-03-01	PHASE2
NCT07090538	NOT_YET_RECRUITING	Neuroblastoma	Chinese PLA General Hospital	2025-08-01	EARLY_PHASE1
NCT03485677	COMPLETED	Gaucher's Disease Type I; Gaucher's Disease Type III	Sanofi	2018-04-11	PHASE3
NCT06523517	UNKNOWN	Gaucher Disease	Peking Union Medical College Hospital	2024-08-01	PHASE2
NCT04944888	COMPLETED	Solid Tumor; Hematologic Malignancy	Chinese PLA General Hospital	2021-07-01	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):